Ayman Al‐Shurbaji
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Potassium and Related Disorders, Pharmacogenetics and Drug Metabolism, Membrane-based Ion Separation Techniques, Liver Disease Diagnosis and Treatment, Hormonal Regulation and Hypertension
Most-Cited Works
- → Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs(2002)578 cited
- → A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia(2019)143 cited
- → Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial(2013)102 cited
- → Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An 11-Month Open-Label Extension of HARMONIZE(2019)82 cited
- → On the mechanism of the hypolipidemic effect of sulfur-substituted hexadecanedioic acid (3-thiadicarboxylic acid) in normolipidemic rats(1993)62 cited
- → Effect of n−3 fatty acids on the key enzymes involved in cholesterol and triglyceride turnover in rat liver(1991)56 cited
- → Regulation of fatty acid oxidation and triglyceride and phospholipid metabolism by hypolipidemic sulfur-substituted fatty acid analogues(1990)52 cited
- → Hepatic Fatty Acid Metabolism as a Determinant of Plasma and Liver Triacylglycerol Levels. Studies on Tetradecylthioacetic and Tetradecylthiopropionic Acids(1995)38 cited
- → Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine(2003)37 cited
- → Quantitative Pharmacogenetics of Nortriptyline(2001)32 cited